Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type  2 Diabetes (T2DM): Rationale and Design

ConclusionThe EMPA-ICD study is the first clinical trial to assess the effect of an SGLT2 inhibitor on clinically significant ventricular arrhythmias in patients with T2DM and an ICD.Trial registrationUnique trial number, jRCTs031180120 (https://jrct.niph.go.jp/latest-detail/jRCTs031180120).
Source: Diabetes Therapy - Category: Endocrinology Source Type: research